Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50

ALX Oncology (NASDAQ:ALXO) had its price objective reduced by stock analysts at Stifel Nicolaus from $3.00 to $1.50 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 41.51% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. UBS Group decreased their price objective on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating on the stock in a report on Monday, January 27th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of ALX Oncology in a research note on Friday. Piper Sandler lifted their price objective on ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Friday, January 24th. Finally, Jefferies Financial Group raised ALX Oncology from a “hold” rating to a “buy” rating and lifted their target price for the company from $2.00 to $3.00 in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, ALX Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $4.14.

ALX Oncology Stock Performance

Shares of ALX Oncology stock opened at $1.06 on Friday. The business’s fifty day simple moving average is $1.39 and its 200-day simple moving average is $1.61. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm has a market cap of $55.91 million, a PE ratio of -0.36 and a beta of 1.01. ALX Oncology has a 52 week low of $0.95 and a 52 week high of $17.83.

Institutional Investors Weigh In On ALX Oncology

Several large investors have recently bought and sold shares of ALXO. Two Sigma Investments LP grew its position in shares of ALX Oncology by 6.7% during the fourth quarter. Two Sigma Investments LP now owns 704,131 shares of the company’s stock worth $1,176,000 after buying an additional 44,072 shares in the last quarter. Two Sigma Advisers LP lifted its stake in ALX Oncology by 64.6% in the fourth quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock worth $1,376,000 after acquiring an additional 323,400 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in ALX Oncology by 55.6% during the 4th quarter. Nuveen Asset Management LLC now owns 164,790 shares of the company’s stock worth $275,000 after acquiring an additional 58,896 shares in the last quarter. Deutsche Bank AG increased its position in shares of ALX Oncology by 521.0% in the 4th quarter. Deutsche Bank AG now owns 101,113 shares of the company’s stock valued at $169,000 after purchasing an additional 84,830 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of ALX Oncology in the 4th quarter valued at $125,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.